SCHEMBL2244136

SCHEMBL2244136

COc1ccc(NS(=O)(=O)CC(=O)O)cc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
LMNA P02545 4/20 0.45
HTT P42858 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
ESR1 P03372 1/20 0.45
TP53 P04637 1/20 0.45
RAB9A P51151 1/20 0.45
ESR2 Q92731 1/20 0.45
F2 P00734 3/20 0.43
PRSS1 P07477 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831093 0.86 GAA (0.51) LMNAHTTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1636450 0.83 L3MBTL1 (0.43) LMNAHTTL3MBTL1SMN1; SMN2HTR6
SCHEMBL1122405 0.83 LMNA (0.48) LMNAHTTL3MBTL1ALDH1A1RAB9A
SCHEMBL19169291 0.79 CA1 (0.54) CA1CA2MMP1MMP2MMP9
SCHEMBL2212133 0.79 ALDH1A1 (0.56) LMNAL3MBTL1ALDH1A1SMN1; SMN2NPC1
SCHEMBL831738 0.78 FFAR4 (0.42) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL8013861 0.77 KCNH2 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL9464585 0.77 CA1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL1635181 0.76 SMN1; SMN2 (0.41) LMNAHTTL3MBTL1SMN1; SMN2ALOX15
SCHEMBL829810 0.76 CA1 (0.54) CA1CA2LMNAHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534284-B1 AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS UNIV TEMPLE (US) 2011-07-27 EP disclosed
US-7161031-B2 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-01-09 US disclosed
EP-1534284-A4 AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS UNIV TEMPLE (US) 2006-08-16 EP disclosed
EP-1534284-A2 AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS Temple University of the Commonwealth System of Higher Education (US) 2005-06-01 EP disclosed
US-20050096484-A1 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders ONCONOVA THERAPEUTICS, INC. 2005-05-05 US disclosed
WO-2003072063-A2 AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096484-A1 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders ARSA, MKI67, CCNA1 CA1 4180/4885CA2 3707/4885MMP1 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.